This highly populated country is growing twice as fast as the United States. Plus, this global economic powerhouse keeps beating forecasts.
Yet over the past two years, one analyst after another – except for yours truly – has sounded the alarm and told investors to stay far, far away.
I’m starting to think that Wall Street just doesn’t understand China – or Frontier Investing… at all.
Are we even looking at the same data?
China just saw first-quarter GDP growth rate of 6.9%
That was its fastest pace of economic expansion since the third quarter of 2015… it was more than 5% above the nation’s own forecasts… and it came at a time when President Donald Trump was still blaming the world’s most populous country for unfair trade programs.
Most established cancer treatments – from chemotherapy and radiation to the 200 drugs out there — have one thing in common.
They’re all more or less “one size fits all” treatments, procedures, or regimens.
But the most exciting, promising discoveries – and biggest profits – are made on the frontier. And on the frontier of cancer research is a treatment under development that’s going to disrupt the field for the next several decades.
I’m talking about powerful “bespoke” cancer treatments for every patient, using their own bodies to boot.
Not only will this improve and save lives, but it’ll also crack open a market worth $25 billion by 2025. It really is a revolutionary development.
As the song goes, “You can’t always get what you want.”
This applies well to last week’s announcement of plans for full legalization of adult marijuana use in Canada. During that April 13 event, the Trudeau government said all will be in place by July 1, 2018.
But there was a “problem” – at least according to some legalization advocates and analysts.
Instead of laying everything out precisely, legalization in Canada is still evolving. For instance, individual Canadian provinces will have a lot of say about where and when marijuana can be sold, how old buyers can be, and taxation.
So there is much more work to do than was hinted by the government when it leaked preliminary legalization details back on March 27.
And out come the handwringers – fretting that legalization will be delayed or… maybe… never even happen.
It’s a deceptively simple, powerful approach I use to help my Nova-X Reportreaders make fast fortunes: Research a good investment, build a thesis, target the best stock before Wall Street analysts know it exists, and let the profits come to you as the crowd piles in.
Silicon Valley is a hotbed of this kind of investing – one where my readers have been able to make a killing. Biotech, rare earths, and cryptocurrencies are three others.
Cannabis investing is the latest and most profitable.
It’s easier now than it’s ever been to get wired into the growth of the legal marijuana sector.
And even after the sweep of states legalizing cannabis on Nov. 8, there’s plenty more of that growth on the way.
When most investors think of the booming legal cannabis sector, they don’t automatically think “high tech” or the life sciences.
That’s a mistake – a potentially costly one.
For one thing, cannabinoids can be used to treat all sorts of ailments, from cancer to arthritis to insomnia. Then there are all the high-tech applications exploding in the growth and consumption of legal marijuana.
But more importantly, cannabis investing is out on the “frontier.”
We’ve been looking at legal marijuana stocks a lot lately.
If you need a reminder as to why, well, look at this…
In 2013, the market for medically “sanctioned’ marijuana was worth about $1.5 billion. It’s expected to reach $6.7 billion this year – and $35 billion by 2020. And by 2029: The market is projected to reach $100 billion.